Fusion Pharmaceuticals/FUSN

$12.10

-4.35%
-
1D1W1MYTD1YMAX

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.

Ticker

FUSN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Valliant

Employees

102

Headquarters

Hamilton, Canada

FUSN Metrics

BasicAdvanced
$879.01M
Market cap
-
P/E ratio
-$1.63
EPS
-0.84
Beta
-
Dividend rate

What the Analysts think about FUSN

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 12 analysts.
19.83% upside
High $20.00
Low $10.00
$12.10
Current price
$14.50
Average price target

FUSN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-860% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$2M
∞%
Net income
$-17.2M
-31.47%
Profit margin
-860%
-∞%

FUSN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 37.36%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.55
-$0.45
-$0.38
-$0.25
-
Expected
-$0.56
-$0.32
-$0.39
-$0.40
-$0.33
Surprise
-1.08%
41.73%
-2.29%
-37.36%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Fusion Pharmaceuticals stock

Buy or sell Fusion Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing